Sutro Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sutro Biopharma (STRO).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy

10Buy

1Hold

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$53Upside to Avg. PT+467.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$60
Aug 13, 2026	Citizens	Reni J. Benjamin	PT Cut	Market Outperform	$41→$34
Aug 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$60
Jun 11, 2026	Truist Securities	Supawat Thongthip	Assumes	Buy	$50
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$56
May 15, 2026	Leerink Partners	—	PT Raise	Outperform	$38→$43
May 15, 2026	Wedbush	David Nierengarten	Upgrade	Neutral→Outperform	$22→$60
May 15, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$28→$50
Apr 30, 2026	Mizuho	Salim Syed	Initiate	Outperform	$50
Apr 23, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$35→$41
Apr 17, 2026	Citizens	Reni J. Benjamin	PT Raise	Market Outperform	$23→$35
Apr 7, 2026	Leerink Partners	—	Initiate	Outperform	$38
Mar 25, 2026	Deutsche Bank	James Shin	PT Raise	Buy	$51→$55
Mar 24, 2026	Wells Fargo	Eva Fortea Verdejo	Upgrade	Equal-Weight→Overweight	$8→$27
Mar 24, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Upgrade	Neutral→Buy	$10→$28
Jan 20, 2026	Citizens	Reni Benjamin	Upgrade	Market Perform→Market Outperform	$23
Dec 22, 2025	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Neutral	$2→$10
Aug 12, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$40→$30
Jun 16, 2025	Piper Sandler	Edward Tenthoff	Upgrade	Neutral→Overweight	$20
May 19, 2025	B of A Securities	Tazeen Ahmad	PT Cut	Underperform	$10→$8

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.

Benzinga Newsdesk

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price target from $38 to $43.

Benzinga Newsdesk

Sutro Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sutro Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

People Also Watch

People Also Watch

Sutro Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Sutro Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PROCitizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PROWedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PROTruist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PROBarclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PROLeerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43

People Also Watch

People Also Watch

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

PRO
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

PRO
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50

PRO
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

PRO
Leerink Partners Maintains Outperform on Sutro Biopharma, Raises Price Target to $43